Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines
F Passiglia, S Pilotto, F Facchinetti… - Critical Reviews in …, 2020 - Elsevier
Abstract The Italian Association of Medical Oncology (AIOM) has developed clinical practice
guidelines for the treatment of patients with advanced non-small cell lung cancer (NSCLC) …
guidelines for the treatment of patients with advanced non-small cell lung cancer (NSCLC) …
Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced EGFR …
F Chen, N Chen, Y Yu, J Cui - Frontiers in Oncology, 2020 - frontiersin.org
Background: Tyrosine kinase inhibitors (TKIs) are standard treatment options for non-small
cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations …
cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations …
The predictive value of [18F]FDG PET/CT radiomics combined with clinical features for EGFR mutation status in different clinical staging of lung adenocarcinoma
J Gao, R Niu, Y Shi, X Shao, Z Jiang, X Ge, Y Wang… - EJNMMI research, 2023 - Springer
Background This study aims to construct radiomics models based on [18F] FDG PET/CT
using multiple machine learning methods to predict the EGFR mutation status of lung …
using multiple machine learning methods to predict the EGFR mutation status of lung …
TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors
On-target resistance to next-generation TRK inhibitors in TRK fusion–positive cancers is
largely uncharacterized. In patients with these tumors, we found that TRK xDFG mutations …
largely uncharacterized. In patients with these tumors, we found that TRK xDFG mutations …
[HTML][HTML] Hype or hope–Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant …
F Papini, J Sundaresan, A Leonetti, M Tiseo… - Critical Reviews in …, 2021 - Elsevier
Three generations of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-
TKIs) have been developed for treating advanced/metastatic non-small cell lung cancer …
TKIs) have been developed for treating advanced/metastatic non-small cell lung cancer …
Subregional radiomics analysis for the detection of the EGFR mutation on thoracic spinal metastases from lung cancer
The present study intended to use radiomic analysis of spinal metastasis subregions to
detect epidermal growth factor receptor (EGFR) mutation. In total, 94 patients with thoracic …
detect epidermal growth factor receptor (EGFR) mutation. In total, 94 patients with thoracic …
Next‐Generation Cancer‐Specific Hybrid Theranostic Nanomaterials: MAGE‐A3 NIR Persistent Luminescence Nanoparticles Conjugated to Afatinib for In Situ …
The rate of lung cancer has gradually increased in recent years, with an average annual
increase of 15%. Afatinib (AFT) plays a key role in preventing non‐small cell lung carcinoma …
increase of 15%. Afatinib (AFT) plays a key role in preventing non‐small cell lung carcinoma …
Targeting micro-environmental pathways by PROTACs as a therapeutic strategy
Tumor microenvironment (TME) composes of multiple cell types and non-cellular
components, which supports the proliferation, metastasis and immune surveillance evasion …
components, which supports the proliferation, metastasis and immune surveillance evasion …
[HTML][HTML] PHLDB2 mediates cetuximab resistance via interacting with EGFR in latent metastasis of colorectal cancer
M Luo, Z Huang, X Yang, Y Chen, J Jiang… - Cellular and molecular …, 2022 - Elsevier
Background & Aims Latent metastasis of colorectal cancer (CRC) frequently develops
months or years after primary surgery, followed by adjuvant therapies, and may progress …
months or years after primary surgery, followed by adjuvant therapies, and may progress …
ALK phosphorylates SMAD4 on tyrosine to disable TGF-β tumour suppressor functions
Q Zhang, M Xiao, S Gu, Y Xu, T Liu, H Li, Y Yu… - Nature Cell …, 2019 - nature.com
Loss of TGF-β tumour suppressive response is a hallmark of human cancers. As a central
player in TGF-β signal transduction, SMAD4 (also known as DPC4) is frequently mutated or …
player in TGF-β signal transduction, SMAD4 (also known as DPC4) is frequently mutated or …